argenx SE (NASDAQ:ARGX) Shares Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company raised its holdings in shares of argenx SE (NASDAQ:ARGX - Free Report) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,113 shares of the company's stock after purchasing an additional 527 shares during the quarter. The Manufacturers Life Insurance Company owned 0.10% of argenx worth $38,199,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. FMR LLC lifted its position in shares of argenx by 17.2% in the 4th quarter. FMR LLC now owns 5,618,222 shares of the company's stock worth $3,455,207,000 after purchasing an additional 824,750 shares during the period. Capital World Investors boosted its position in argenx by 5.1% during the 4th quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after acquiring an additional 86,687 shares in the last quarter. Clearbridge Investments LLC boosted its position in argenx by 6.8% during the 4th quarter. Clearbridge Investments LLC now owns 629,828 shares of the company's stock valued at $387,344,000 after acquiring an additional 40,330 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company's stock valued at $185,821,000 after buying an additional 64,183 shares in the last quarter. Finally, Lord Abbett & CO. LLC increased its position in shares of argenx by 26.5% during the fourth quarter. Lord Abbett & CO. LLC now owns 206,202 shares of the company's stock worth $126,814,000 after purchasing an additional 43,239 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ARGX has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft raised argenx from a "sell" rating to a "hold" rating in a research report on Wednesday, March 12th. Piper Sandler upped their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 7th. Sanford C. Bernstein upgraded argenx from a "market perform" rating to an "outperform" rating in a report on Monday, March 17th. Wells Fargo & Company boosted their price target on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research report on Friday, February 28th. Finally, Guggenheim upped their price target on argenx from $775.00 to $1,100.00 and gave the company a "buy" rating in a research report on Monday, March 10th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, argenx has an average rating of "Moderate Buy" and a consensus price target of $699.28.

argenx Stock Down 3.2 %

Shares of ARGX traded down $20.82 during midday trading on Tuesday, hitting $635.83. The company had a trading volume of 164,365 shares, compared to its average volume of 309,018. The stock has a market cap of $38.82 billion, a price-to-earnings ratio of -725.79 and a beta of 0.57. The company's 50 day moving average price is $598.99 and its 200 day moving average price is $612.98. argenx SE has a 52 week low of $352.77 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.98 by $0.60. The firm had revenue of $761.22 million for the quarter, compared to analysts' expectations of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Equities analysts anticipate that argenx SE will post 3.13 EPS for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.